
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
5
Neutral
5
Bullish
4
Bearish
6
Neutral
5
Bullish
35
Bearish
1
Neutral
0
Bullish
31
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Inventurus Knowledge Solutions Ltd (IKS) is currently trading at 1,677.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Inventurus Knowledge Solutions Limited provides a tech-enabled healthcare provider enablement platform primarily to U.S.-based healthcare organizations. It focuses on enhancing operational efficiency across inpatient and outpatient care. IKS Health's recent strategic focus includes an AI-driven transformation of its platform, recognized by Google Cloud, integrating autonomous clinical documentation and revenue cycle management workflows. The company's acquisition of AQuity Holdings two years ago significantly advanced its operational model, leading to improved margins and expanded service offerings. IKS Health demonstrated strong performance with revenue growth of 22% YoY in Q2 FY '26, accompanied by a 43% increase in EBITDA and consistent client engagement. Acknowledged for strategic collaborations, IKS Health is strengthening its market presence through partnerships with major healthcare systems, enhancing its comprehensive platform offerings.
Over the past 52 weeks, Inventurus Knowledge Solutions Ltd has traded between a low of ₹1,226.15 and a high of ₹1,927.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Inventurus Knowledge Solutions Ltd has a market capitalization of approximately 28,805.94. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Inventurus Knowledge Solutions Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.40 and operates in the IT - Software sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
You can buy shares of Inventurus Knowledge Solutions Ltd (IKS) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.
Based on its market capitalization of 28,805.94 Cr, Inventurus Knowledge Solutions Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Inventurus Knowledge Solutions Ltd operates in the IT - Software sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Inventurus Knowledge Solutions Ltd is 43.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Inventurus Knowledge Solutions Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.
Key risks associated with Inventurus Knowledge Solutions Ltd include sector-specific challenges in the IT - Software industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.
IT - Software
IT Enabled Services / Business Process Outsourcing
28,806 Cr
Low Risk
43.4
26.2
2.1
12.9
1,927.00
1,226.15
Sales CAGR
1Y
46.54%
3Y
20.21%
5Y
20.22%
10Y
—
Profit CAGR
1Y
31.19%
3Y
20.68%
5Y
22.14%
10Y
—
ROE
TTM
27.21%
3Y
34.23%
5Y
34.84%
10Y
—
ROCE
TTM
27.85%
3Y
38.39%
5Y
37.98%
10Y
—
Market Cap
₹ 28,806 Cr
P/E
43.40
Performance
STEADY PERFORMER
Valuation
OVERVALUED
Growth
STABLE
Profitability
HIGH MARGIN
Technicals
Bullish
Risk
MODERATE RISK
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Financial Results
1 day ago
Unaudited Financial Results Released
The unaudited financial results for the quarter and nine months ended December 31, 2025, were published in newspapers on February 6, 2026.
Investor Presentation
3 days ago
Q3 FY 26 Investor Presentation Released
The company disclosed its Q3 FY 26 financial results and growth strategies in an investor presentation, highlighting continuous margin expansion and strong cash generation.
Financial Results
3 days ago
IKS Health Announces Strong Q3 FY26 Financial Results
IKS Health reports 24% revenue growth and 41% PAT increase for Q3 FY26, showcasing robust financial performance.
Financial Results
3 days ago
Quarterly and Nine-Month Financial Results Released
The company has disclosed its unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025, following a Board meeting.
Board Meeting Outcome
3 days ago
Board Meeting Results for Q3 FY2026
The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, during a meeting on February 4, 2026.
Investor Meeting
4 days ago
Schedule of Analyst/Investor Meet
Announcement regarding the Analyst/Institutional Investor Meet on February 10, 2026, at the Axis Capital Conference in Mumbai.